Medicare Enrolled
Dr. Rohini Chintalapally, MD
Hematology & Oncology · Douglasville, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chintalapally from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chintalapally?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chintalapally
Dr. Rohini Chintalapally is a hematology & oncology specialist in Douglasville, GA, with 14 years of NPI registration. Based on federal Medicare data, Dr. Chintalapally performed 608 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Chintalapally received a total of $8,010 from 60 pharmaceutical and/or device companies across 347 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chintalapally is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years of NPI registration
▲ 608 Medicare services
$8,010 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗608
Medicare services
Bottom 42% in GA for hematology & oncology
Not available
Unique patients (not deduplicated)
$90
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
301 | $73 | $284 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
76 | $111 | $385 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
66 | $64 | $180 |
| New patient office visit, complex (60-74 min) | 64 | $142 | $480 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
38 | $140 | $452 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
36 | $95 | $257 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
15 | $95 | $378 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $51 | $203 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
Industry Payment Transparency
Open Payments through 2024 ↗$8,010
Total received (2018-2024)
Avg $1,144/year across 7 years
Top 36% in GA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
347
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,131
2023
$1,667
2022
$1,990
2021
$544
2020
$47
2019
$385
2018
$247
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$715
Daiichi Sankyo Inc.
$263
PFIZER INC.
$224
SOBI, INC
$219
Novartis Pharmaceuticals Corporation
$218
ABBVIE INC.
$149
Rigel Pharmaceuticals, Inc.
$120
Janssen Biotech, Inc.
$117
Takeda Pharmaceuticals U.S.A., Inc.
$113
Genentech USA, Inc.
$107
Merck Sharp & Dohme LLC
$97
Eisai Inc.
$84
JAZZ PHARMACEUTICALS INC.
$81
Gilead Sciences, Inc.
$61
E.R. Squibb & Sons, L.L.C.
$50
Regeneron Healthcare Solutions, Inc.
$47
GlaxoSmithKline, LLC.
$47
Incyte Corporation
$45
Alexion Pharmaceuticals, Inc.
$44
TerSera Therapeutics LLC
$33
Astellas Pharma US Inc
$30
Acrotech Biopharma Inc.
$28
Lilly USA, LLC
$25
PUMA BIOTECHNOLOGY, INC.
$24
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
Stemline Therapeutics Inc.
$21
GENZYME CORPORATION
$19
Exelixis Inc.
$19
Karyopharm Therapeutics Inc.
$19
Genmab U.S., Inc.
$16
BeiGene USA, Inc.
$16
ARRAY BIOPHARMA INC
$16
Adaptive Biotechnologies Corporation
$16
Bayer Healthcare Pharmaceuticals Inc.
$15
Mirati Therapeutics, Inc.
$13
Top 3 companies account for 38.4% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$765
Amgen Inc.
$500
Genentech USA, Inc.
$469
Janssen Biotech, Inc.
$466
Daiichi Sankyo Inc.
$458
PFIZER INC.
$433
Novartis Pharmaceuticals Corporation
$378
Seagen Inc.
$316
SOBI, INC
$262
E.R. Squibb & Sons, L.L.C.
$252
GlaxoSmithKline, LLC.
$247
Eisai Inc.
$231
Merck Sharp & Dohme LLC
$204
Takeda Pharmaceuticals U.S.A., Inc.
$197
Celgene Corporation
$188
Regeneron Healthcare Solutions, Inc.
$183
Gilead Sciences, Inc.
$173
Pharmacyclics LLC, An AbbVie Company
$164
ABBVIE INC.
$149
Rigel Pharmaceuticals, Inc.
$140
GENZYME CORPORATION
$119
JAZZ PHARMACEUTICALS INC.
$103
Coherus Biosciences Inc.
$93
Exelixis Inc.
$90
G1 Therapeutics, Inc.
$81
Lilly USA, LLC
$81
ARRAY BIOPHARMA INC
$79
Mirati Therapeutics, Inc.
$71
Adaptive Biotechnologies Corporation
$68
Alexion Pharmaceuticals, Inc.
$67
Astellas Pharma US Inc
$66
EISAI INC.
$66
BeiGene USA, Inc.
$61
Pharmacyclics LLC, an AbbVie Company
$56
AbbVie Inc.
$53
Kite Pharma, Inc.
$51
Bayer HealthCare Pharmaceuticals Inc.
$47
Incyte Corporation
$45
PUMA BIOTECHNOLOGY, INC.
$43
CTI BioPharma Corp.
$40
Stemline Therapeutics Inc.
$40
Bayer Healthcare Pharmaceuticals Inc.
$35
TerSera Therapeutics LLC
$33
Deciphera Pharmaceuticals Inc.
$31
Seattle Genetics, Inc.
$29
Acrotech Biopharma Inc.
$28
Amarin Pharma Inc.
$22
Veran Medical Technologies, Inc.
$22
EUSA Pharma (US) LLC
$21
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
Sobi, Inc
$21
Organon LLC
$20
Epizyme, Inc.,
$19
ADC Therapeutics America, Inc.
$19
Karyopharm Therapeutics Inc.
$19
Mylan Institutional Inc.
$17
Agios Pharmaceuticals, Inc.
$17
Genmab U.S., Inc.
$16
TG THERAPEUTICS, INC.
$14
Clovis Oncology, Inc.
$11
Top 3 companies account for 21.7% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · Alecensa · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · Epkinly · FRUZAQLA · Fabhalta · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Itovebi · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · NERLYNX · NINLARO · Neulasta · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · OXBRYTA · Ogivri · Orserdu · PADCEV · PROMACTA · PYRUKYND · Padcev · Phesgo · Polivy · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · Reblozyl · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SPRYCEL · Spin · Stivarga · Sylvant · TAGRISSO · TAZVERIK · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VONJO · Vascepa · Venclexta · Vonjo · XALKORI · XOSPATA · XPOVIO · XTANDI · Yescarta · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
97
County median income
$80,764
Nearest hospital to ZIP centroid (approximate)
WELLSTAR DOUGLAS MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chintalapally is a clinical cardiology specialist, with moderate Medicare volume.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chintalapally experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Chintalapally performed 301 office visit, established patient (30-39 min) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Chintalapally receive payments from pharmaceutical companies?
Yes. Dr. Chintalapally received a total of $8,010 from 60 companies across 347 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chintalapally's costs compare to other hematology & oncology specialists in Douglasville?
Dr. Chintalapally's average Medicare payment per service is $90. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chintalapally) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Douglasville
Browse hematology & oncology specialists in Douglasville ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology